The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 03, 2019

Filed:

Feb. 03, 2017
Applicant:

The Government of the U.s.a. As Represented BY the Secretary of the Dept. of Health and Human Services, Bethesda, MD (US);

Inventors:

Dimiter S. Dimitrov, Frederick, MD (US);

Xiaodong Xiao, Frederick, MD (US);

Ira H. Pastan, Potomac, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 38/16 (2006.01); A61K 38/45 (2006.01); G01N 33/574 (2006.01); A61K 47/68 (2017.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 38/164 (2013.01); A61K 38/45 (2013.01); A61K 47/6829 (2017.08); A61K 47/6849 (2017.08); A61K 47/6867 (2017.08); C07K 16/2896 (2013.01); C12Y 204/02036 (2013.01); G01N 33/57492 (2013.01); A61K 39/00 (2013.01); A61K 39/39558 (2013.01); A61K 2039/505 (2013.01); C07K 16/28 (2013.01); C07K 2317/21 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70503 (2013.01);
Abstract

Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (K) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.


Find Patent Forward Citations

Loading…